Skip to main content
Celcuity Inc. logo

Celcuity Inc. — Investor Relations & Filings

Ticker · CELC ISIN · US15102K1007 LEI · 25490070W7UU7W2SEY87 US Professional, scientific and technical activities
Filings indexed 484 across all filing types
Latest filing 2023-02-02 Major Shareholding Noti…
Country US United States of America
Listing US CELC

About Celcuity Inc.

https://www.celcuity.com/

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company's approach centers on the PI3K/AKT/mTOR (PAM) pathway, a critical signaling cascade involved in cancer cell growth and survival. Its lead product candidate, gedatolisib, is a potential first-in-class, pan-PI3K and mTORC1/2 inhibitor designed to comprehensively blockade the PAM pathway. Celcuity's pipeline is advancing treatments with a focus on breast and prostate cancers.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A
Major Shareholding Notification
2023-02-02 English
Regulatory Filings 2023
Regulatory Filings
2023-01-13 English
Prospectus 2023
Prospectus
2023-01-12 English
Regulatory Filings 2023
Regulatory Filings
2023-01-09 English
Regulatory Filings 2023
Regulatory Filings
2023-01-05 English
Registration Form 2022
Registration Form
2022-12-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.